Search - tctmd.com

Displaying 101 - 120 of 558

Sort: Relevancy | Date

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

TCTMD’s Top 10 Most Popular Stories for October 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

November 01, 2024

October 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

October 25, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

AHA Statement Outlines Cardiac Contributions to Brain Health

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

October 11, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

TCTMD’s Top 10 Most Popular Stories for September 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

October 01, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

News Daily News

Lingering Gaps in CVD Care for Women Spotlighted in British Consensus Statement

September 26, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

August 31, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.